Food Allergy Treatment Market Report 2026

The food allergy treatment market size has grown rapidly in recent years. It will grow from $7.6 billion in 2025 to $8.5 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to growth in food allergy prevalence, availability of antihistamines, adoption of epinephrine therapy, increased allergy diagnosis rates, clinical guideline development.

The food allergy treatment market size is expected to see rapid growth in the next few years. It will grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to innovation in oral immunotherapy, expansion of biologic treatments, growth in pediatric allergy care, demand for long-term allergy management, increasing healthcare access. Major trends in the forecast period include rising adoption of immunotherapy-based treatments, increased use of epinephrine auto-injectors, growing focus on preventive allergy management, expansion of personalized allergy treatment plans, increased awareness of food allergy conditions.

The rising incidence of food adulteration is expected to drive growth in the food allergy treatment market in the coming years. Food adulteration involves the intentional alteration of food products by adding inferior, harmful, or unauthorized substances, or by removing essential ingredients, to increase quantity or improve appearance, often compromising quality and safety. The increase in food adulteration is driven by factors such as economic incentives, complex supply chains, inadequate regulation, technological advancements, growing demand for convenience foods, globalization, environmental influences, consumer awareness gaps, profit pressures, and weak regulatory enforcement. A key contributor is the rising demand for low-cost food products, which encourages unethical practices aimed at reducing costs and maximizing profits. Food adulteration heightens the risk of allergic reactions by introducing undeclared allergens or undermining the safety and integrity of the food supply. For example, in 2023, the FDA CORE Network, a US-based government agency, reported that it evaluated 69 incidents, responded to 25, and issued 10 public health advisories, compared with 65 incidents, 28 responses, and 11 advisories in 2022. Therefore, the growing prevalence of food adulteration is fueling the expansion of the food allergy treatment market.

Leading companies in the food allergy treatment market are focusing on the development of innovative therapies, such as monoclonal antibodies, to target the underlying immune mechanisms responsible for food allergies and deliver more effective treatment options. Monoclonal antibodies offer a promising therapeutic approach by selectively targeting key components of the immune system involved in allergic responses, enabling more precise and effective management of food allergies. For instance, in February 2024, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Xolair (omalizumab) to reduce IgE-mediated food allergies. Xolair is a humanized monoclonal antibody administered subcutaneously that works by blocking IgE binding, thereby reducing the release of allergy-triggering chemicals. The approval was supported by positive Phase III OUtMATCH trial data, demonstrating that a significantly higher proportion of food allergy patients as young as one year old treated with Xolair could tolerate small amounts of peanut, milk, egg, and cashews without experiencing allergic reactions compared to placebo.

In September 2023, Stallergenes Greer, a Switzerland-based biopharmaceutical company, acquired a peanut allergy treatment business from Nestlé for an undisclosed sum. This acquisition enables Nestlé to concentrate on its core business priorities while allowing Stallergenes Greer to strengthen and broaden its allergy treatment portfolio. Nestlé is a Switzerland-based company with activities focused on food allergy prevention and treatment.

Major companies operating in the food allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., ALK-Abelló A/S, Stallergenes Greer, Kaleo Inc., HAL Allergy B.V., Vedanta Biosciences Inc., Aimmune Therapeutics, AnaptysBio Inc., Immunomic Therapeutics Inc., Alladapt Immunotherapeutics Inc., Aravax, Prota Therapeutics Pty Ltd., DBV Technologies, Adamis Pharmaceuticals Corporation.

North America was the largest region in the food allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the food allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the food allergy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the food allergy treatment market by raising prices for imported antihistamines, epinephrine auto-injectors, immunotherapy products, and pharmaceutical ingredients. Hospital and retail pharmacies in Asia-Pacific and emerging regions are most affected due to dependence on global drug manufacturers. These higher costs can reduce patient access to life-saving therapies. However, tariffs are promoting domestic drug production and device assembly, strengthening long-term supply reliability.

The food allergy treatment market research report is one of a series of new reports that provides food allergy treatment market statistics, including food allergy treatment industry global market size, regional shares, competitors with a food allergy treatment market share, detailed food allergy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the food allergy treatment industry. This food allergy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Food allergy treatment involves medical interventions and approaches used to prevent, manage, and treat allergic reactions caused by specific foods. The primary aim of food allergy treatment is to minimize the frequency and severity of allergic reactions, enhance the quality of life for affected individuals, and improve overall patient safety.

The main drug types used in food allergy treatment include antihistamines, decongestants, corticosteroids, mast cell stabilizers, leukotriene inhibitors, nasal anticholinergics, immunomodulators, epinephrine, and immunotherapy. Antihistamines are a class of medications used to relieve symptoms associated with allergic reactions. They can be administered through oral and parenteral routes to address allergies caused by various foods, including dairy products, poultry products, tree nuts, peanuts, shellfish, wheat, soy, and others, and are distributed through hospital pharmacies, retail pharmacies, and other end-users.

The food allergy treatment market consists of revenues earned by entities by providing services such as diagnostic testing, pharmaceutical treatments, immunotherapy, nutritional supplements, emergency kits, educational programs, dietary counseling, telemedicine solutions, and research and development efforts. The market value includes the value of related goods sold by the service provider or included within the service offering. The food allergy treatment market also includes sales of medical devices, such as epinephrine auto-injectors, allergy management kits, and medical alert accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.